SUD Treatment Benefits Combined With Chiropractic Care

Find out how SUD treatment combined with integrative chiropractic care supports mental and physical well-being in recovery.

Abstract

Welcome to this comprehensive exploration of modern approaches to Substance Use Disorder (SUD) care. My name is Dr. Alex Jimenez, and with my extensive background in chiropractic, functional, and family medicine, I am passionate about integrating diverse healthcare disciplines to achieve optimal patient outcomes. In this educational post, I will walk you through an integrative, evidence-based framework for improving care transitions for individuals with SUDs, including those navigating acute-to-community care, justice reentry, pregnancy and postpartum recovery, and adolescent care. We will journey through the evolving landscape of SUD treatment, examining the critical role of advanced practice providers like Nurse Practitioners (NPs), the power of multidisciplinary care models, and the latest findings from leading researchers.

We will focus on best practices for care transitions, innovative treatment strategies like Medications for Opioid Use Disorder (MOUD), and the physiological underpinnings of addiction. A central theme will be integrating chiropractic care within a broader, collaborative framework that includes medical oversight, functional medicine, and rehabilitation. This model, which we practice at our clinic, demonstrates how treating the whole person—addressing structural, biochemical, and psychosocial factors—is essential for lasting recovery. I will also detail the nuanced legal and ethical dimensions of peripartum care, emphasizing non-judgmental, person-centered strategies. Throughout, I describe how our multidisciplinary team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso integrates chiropractic care, internal medicine oversight, functional medicine, and rehabilitation to deliver comprehensive, patient-centered transitions of care. This educational journey is designed to be clear, insightful, and empowering for both healthcare professionals and patients seeking a deeper understanding of addiction and recovery.

Introduction: A New Paradigm in Patient Care

As a clinician with dual licensure as a Doctor of Chiropractic (DC) and an Advanced Practice Registered Nurse (APRN) specializing as a Family Nurse Practitioner (FNP-BC), I have dedicated my career to building bridges between different fields of medicine. My additional certifications in functional medicine (CFMP, IFMCP) and other specialized areas, such as Advanced Trauma Nursing (ATN) and Chiropractic Clinical Science and Technology (CCST), have reinforced my belief in a holistic, patient-centered model of care. At our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic), here in El Paso, Texas, we have cultivated a unique and powerful multidisciplinary environment.

Our Medical Director, Dr. Maria Guadalupe Cardenas, MD, leads this collaborative setup. Dr. Cardenas is a highly respected, board-certified internist with over 40 years of clinical experience (NPI #1164426749, Texas MD License #J2933). Her deep knowledge of internal medicine provides the essential medical oversight that anchors our integrative protocols. Working alongside her, I integrate chiropractic care, functional medicine diagnostics, rehabilitation, and personal injury management. This synergy allows us to address health issues from multiple angles. For instance, while I may focus on the biomechanical and neurological aspects of a patient’s pain through chiropractic adjustments, Dr. Cardenas provides the crucial medical management for underlying conditions like hypertension, diabetes, or, as we will discuss today, the complex physiological challenges of Substance Use Disorder (SUD).

Our team approach is not just a matter of convenience; it is a clinical philosophy. We believe that complex chronic conditions, including SUD, are rarely isolated to a single body system. They involve a cascade of physiological, structural, and psychological dysfunctions. Therefore, our model integrates:

• Medical Oversight (Dr. Cardenas): Providing primary medical care, managing comorbidities (e.g., cardiometabolic disease, infectious disease screening, psychiatric co-management), prescribing necessary medications, and ensuring all treatments adhere to the highest medical standards, including supervision of bridging protocols for MOUD.
• Chiropractic and Structural Care (Dr. Jimenez): Addressing musculoskeletal pain, neurological dysfunction, and the physical stress that often accompanies and drives substance use. This includes pain and movement assessment, spinal adjustments, soft-tissue techniques, and neuromuscular reeducation.
• Functional Medicine: Investigating the root causes of illness, such as nutritional deficiencies, hormonal imbalances, and gut-brain axis dysfunction, to support recovery.
• Rehabilitation and Physical Therapy: Restoring function, improving mobility, and empowering patients through movement, graded exercise exposure, and individualized recovery support that integrates nutrition, sleep, and stress physiology.
• Personal Injury Care: Providing comprehensive care for patients who have suffered injuries, a population often at high risk for developing chronic pain and subsequent SUD.

This integrated framework is particularly relevant to managing SUD, a condition that profoundly impacts every aspect of a person’s health. By combining our expertise, Dr. Cardenas and I can create a robust support system that addresses not just the addiction itself, but the entire person.

The Pivotal Role of Nurse Practitioners in SUD Care

The healthcare landscape in the United States is undergoing a significant transformation, and at the heart of this change is the rapidly growing profession of Nurse Practitioners (NPs). With approximately 258,000 NPs currently in practice and projected growth of 45% over the next decade, this profession is expanding faster than many others. This growth is not just a statistic; it represents a fundamental shift in how healthcare is delivered.

A critical point to understand is that over 70% of NPs provide some form of primary care. This positions us on the front lines, often serving as the first point of contact for patients entering the healthcare system. Consequently, NPs are uniquely positioned to be a crucial entry point for individuals needing Substance Use Disorder (SUD) treatment. This is especially true for those in rural and underserved populations, where access to specialized care is often limited. Our presence in these communities creates an invaluable opportunity to identify, engage, and treat patients who might otherwise fall through the cracks.

The NP Model: A Foundation for Compassionate SUD Treatment

Beyond our sheer numbers and accessibility, the very philosophy underpinning NP education and practice makes us particularly well-suited to provide high-quality SUD care. The nursing model is inherently holistic and patient-centered, built on principles that align perfectly with the needs of individuals struggling with addiction. These core tenets include:

• Valuing Patient Autonomy and Self-Determination: We are trained to see the patient as a partner in their own care. In SUD treatment, this means respecting their readiness to change, involving them in shared decision-making, and empowering them to take ownership of their recovery journey.
• Prioritizing Prevention and Education: A significant part of our role is to educate patients about their health. For SUD, this involves providing clear information about the risks of substance use, the benefits of treatment, and harm reduction strategies. By empowering patients with knowledge, we help them make more informed choices.
• Fostering a Non-Judgmental, Non-Stigmatizing Environment: The stigma associated with SUD is a major barrier to care. NPs are skilled in therapeutic communication, creating a safe space where patients feel comfortable disclosing their struggles without fear of judgment or punishment. This trust is the bedrock of any successful therapeutic relationship.
• Mastery of Motivational Interviewing: Motivational interviewing is a cornerstone of compassionate and effective addiction care. This collaborative, goal-oriented communication style strengthens a person’s motivation and commitment to a specific goal by exploring and resolving ambivalence. It is not about confronting or coercing the patient; it is about guiding them to find their own reasons for change. This technique is deeply embedded in the NP approach to patient care.

State law determines the scope of practice for NPs, including the ability to prescribe controlled substances. Some states require a practice agreement with a collaborating physician, like the one I have with Dr. Cardenas, which fosters a team-based approach. In other states, NPs have full practice autonomy.

A landmark change in recent years has been the elimination of the X-waiver requirement for prescribing buprenorphine, a key medication for opioid use disorder (OUD). This policy change officially recognizes that treating OUD with buprenorphine is firmly within the scope of primary care. This has dramatically increased access to this life-saving treatment, and NPs in a wide variety of settings can now prescribe it.

The regulations for methadone, another effective medication for OUD, are different. Federal law mandates that methadone for OUD must be dispensed from a licensed Opioid Treatment Program (OTP). However, NPs can still play a vital role. Within the hospital setting, and in accordance with state laws, NPs can oversee the initiation and adjustment of methadone for patients admitted for other medical issues who also have OUD. This ensures continuity of care and prevents withdrawal during a hospital stay.

Despite these advancements, the time dedicated to SUD care in many NP programs can be limited because of competing curricular demands. To bridge this gap, dedicated pathways for advanced training exist. NPs can pursue a specialized certification called the Certified Addiction Registered Nurse Advanced Practice (CARN-AP), which demonstrates a high level of expertise in addiction care. Furthermore, Psychiatric Mental Health Nurse Practitioners (PMHNPs) receive extensive training and board certification in the diagnosis and management of SUDs as part of their specialty.

The Healthcare System as a Risk Environment

For many individuals who use substances, the healthcare system is not seen as a place of healing but as a risk environment. This perception is born from negative experiences and a deep-seated fear of judgment and reprisal. When patients with SUD interact with healthcare providers, they often face stigma and discrimination, fear legal punishment, and develop a profound mistrust of the very people who are supposed to help them.

This perception has severe and far-reaching consequences:

• Delaying Care: Patients may avoid seeking medical attention until their health problems become critical, turning preventable issues into life-threatening emergencies.
• Non-Disclosure of Drug Use: Fear of judgment leads patients to hide their substance use from providers. This lack of information can lead to dangerous drug interactions, undertreated withdrawal, and misdiagnosis.
• Minimizing Pain: Patients with a history of SUD may be so afraid of being labeled a “drug-seeker” that they downplay their legitimate pain, leading to inadequate pain management and immense suffering.
• Leaving Against Medical Advice (AMA): The distress and discomfort of being in a hospital, often compounded by poorly managed withdrawal or stigmatizing interactions, can cause patients to leave before their medical treatment is complete, with potentially devastating health outcomes.

The cumulative effect of these behaviors is a cycle of crisis-driven care. Instead of engaging in preventive medicine and addressing health issues early, patients present with more advanced and acute illnesses. This not only results in increased morbidity and mortality for the individual but also drives up costs for the entire healthcare system.

At our clinic, we are acutely aware of these dynamics. Dr. Cardenas and I have worked diligently to create an environment where patients feel safe, heard, and respected, regardless of their history. This is the first and most critical step in breaking down the barriers to effective care.

A Spectrum of Care: From Primary Care to Specialty Treatment

Effective SUD treatment is not a one-size-fits-all solution. It requires a continuum of care options tailored to a patient’s individual needs, resources, and readiness for change. In this model, primary care often serves as the central hub, with connections to more specialized services as needed.

The various settings for SUD care include:

• Primary Care: The foundation for long-term, comprehensive care.
• Hospital/Inpatient and Emergency Department: Critical entry points for initiating treatment during a medical crisis, with a focus on transitioning patients to community-based care.
• Specialty SUD Treatment Facilities: These include intensive outpatient programs (IOP), residential treatment facilities, and other specialized clinics.
• Peer Support Networks: Community-based groups and peer specialists who provide invaluable support and guidance based on lived experience.
• Dedicated Mental Health Services: Addressing co-occurring mental health conditions like depression, anxiety, and trauma, which are often intertwined with SUD.
• Telehealth and Bridge Clinics: Innovative models that use technology to provide immediate access to care, serving as a “bridge” from an acute event (like an overdose or hospital discharge) to long-term treatment.

The ASAM Criteria: Matching Patient to Treatment Level

To determine the most appropriate level of care for a patient, clinicians often use the ASAM Levels of Care Criteria, developed by the American Society of Addiction Medicine. This is not just a simple checklist; it is a comprehensive, multidimensional assessment tool that provides a holistic view of the patient.

The ASAM criteria are strength-based. This means they don’t focus only on a patient’s problems or liabilities. Instead, the assessment evaluates six key dimensions to create a complete picture:

1. Acute Intoxication and/or Withdrawal Potential: What is the patient’s current state of intoxication or risk of withdrawal? Do they need medical management to detoxify safely?
2. Biomedical Conditions and Complications: What other medical problems does the patient have? How do these conditions interact with their SUD?
3. Emotional, Behavioral, or Cognitive Conditions and Complications: Are there co-occurring mental health disorders like depression, anxiety, or psychosis that need to be addressed?
4. Readiness to Change: How motivated is the patient to change their substance use behavior? Are they contemplative, prepared for action, or in need of more motivational work?
5. Relapse, Continued Use, or Continued Problem Potential: What is the risk of the patient returning to use? Do they have the skills to cope with triggers and cravings?
6. Recovery/Living Environment: What is the patient’s living situation? Is it supportive of recovery, or is it filled with triggers and risks? Do they have a strong support system of family and friends?

Based on this multidimensional assessment, the patient is matched to the appropriate level of care on a continuum that ranges from outpatient services (Level 1) to medically managed intensive inpatient treatment (Level 4). This ensures that patients receive the intensity of care they truly need, without being over- or under-treated.

Primary Care: The Untapped Potential for SUD Treatment

As we’ve discussed, primary care providers (PCPs), including the large and growing workforce of NPs, are at the forefront of the U.S. healthcare system. This gives us a unique and powerful opportunity to provide comprehensive SUD care. One of the greatest advantages of the primary care setting is the longitudinal relationship we build with our patients over time.

This long-term relationship means we can meet patients wherever they are on their journey. The trajectory of recovery is rarely a straight line; it is a process of change that unfolds over months or even years. As a PCP, I have the privilege of accompanying my patients through the different stages of change:

• Precontemplation: The patient is not yet considering change. My role here is to build trust and gently raise awareness.
• Contemplation: The patient is ambivalent about change, weighing the pros and cons. Here, the intervention might involve education about the consequences of use, discussing harm reduction, and using motivational interviewing to explore their goals and values.
• Preparation: The patient is committed to making a change and is planning their first steps. We can work together to develop a concrete action plan.
• Action: The patient is actively modifying their behavior. For a patient with OUD who is ready for action, this is when we would discuss evidence-based treatments like buprenorphine or naltrexone to support their efforts.
• Maintenance: The patient has sustained their change and is working to prevent relapse. My role shifts to providing ongoing support, monitoring for challenges, and celebrating their successes.

This ability to tailor interventions to a patient’s specific stage of change is a key strength of the primary care model.

The Sobering Reality: Barriers to SUD Care in Primary Care

Despite this immense potential, very few primary care settings in the U.S. offer a full range of SUD treatments. The statistics are stark: an estimated 86.6% of patients with opioid use disorder who could benefit from medication do not receive it. This is a catastrophic failure of our system. Why does this treatment gap exist?

First, we must address the elephant in the room: the profound shortage of primary care providers. As of 2025 data, over 77 million people in the U.S. live in a Primary Care Health Professional Shortage Area (HPSA). The existing workforce is only meeting about 44.5% of the nation’s need for primary care providers. To close this gap, we would need over 13,000 additional PCPs.

This shortage places an immense burden on existing providers, creating significant barriers to offering comprehensive SUD care:

• Time Constraints: In a busy primary care practice, where appointments are often scheduled in 15-minute slots, the thought of initiating a complex conversation about substance use and starting a new treatment can feel overwhelming.
• Low Reimbursement Rates: Historically, the reimbursement for counseling and addiction treatment services has been low, creating a financial disincentive for practices to invest time and resources in this area.
• Lack of Referral Options: Many PCPs feel they are on an island. They may be willing to start a patient on medication like buprenorphine but have nowhere to refer them for the crucial psychosocial support they need. This feeling of “holding the bag” can be a powerful deterrent.
• Lack of Institutional Support: Without support from clinic management or hospital administration, individual providers struggle to champion and implement SUD services. This includes a lack of protected time, training, and resources.
• Fear of Diversion: Some providers are concerned that patients will take medications like buprenorphine and sell them on the street (divert them). While diversion is a valid concern, the data show that the vast majority of diversion is for the purpose of self-treating withdrawal or managing addiction, highlighting the massive unmet need for treatment.
• Requirements for Concurrent Counseling: In some systems, patients must engage in behavioral counseling to be eligible for medication. While psychosocial support is incredibly valuable, making it a rigid prerequisite can create an unnecessary barrier to life-saving medical treatment.

Best Practices for Integrating SUD Care into Primary Care

Overcoming these barriers is not impossible. A systematic review of successful models for integrating OUD treatment into primary care identified four common components that are crucial for success:

1. Offer Pharmacologic Therapy: This is the cornerstone. Providing evidence-based medications like buprenorphine, naltrexone, and acamprosate is essential.
2. Offer Co-located Psychosocial Services: Integrating mental health counselors, social workers, and therapists into the primary care clinic itself breaks down referral barriers and facilitates seamless care.
3. Integrate Care Options: Services must be more than co-located; they must be truly integrated. This means the medical provider, the counselor, and the care manager are all part of the same team, communicating regularly and working from a shared care plan.
4. Provide Education and Outreach: Proactively educating patients about SUD, treatment options, and harm reduction helps to de-stigmatize the condition and encourage them to seek help.

Successful models almost always employ team-based approaches. A key strategy is using nurse care managers, who can serve as the primary point of contact for patients on buprenorphine. These nurses can handle follow-up calls, coordinate refills, manage urine toxicology screening, and provide ongoing support, which frees up the prescribing provider’s time.

Furthermore, it is vital to support providers and empower SUD champions within an organization. This means providing them with advanced training, protected administrative time to develop programs, and the institutional backing to lead change.

Excellent resources have been developed to support PCPs in this work. One of the most valuable is the Provider Clinical Support System (PCSS). Funded by the Substance Abuse and Mental Health Services Administration (SAMHSA), this program offers a wealth of training, webinars, and clinical tools. A particularly powerful feature is its clinical mentoring program, where any clinician can sign up to be paired with an experienced mentor for free, one-on-one consultation on complex cases, such as buprenorphine initiation and management.

A Clinical Case Study: James’s Journey in an Integrated Primary Care Setting

Let’s walk through a case that illustrates how these best practices can come together in a real-world clinical scenario.

The Initial Visit

James, a 52-year-old man, comes to his primary care appointment at a Federally Qualified Health Center (FQHC) to see his NP. The stated purpose of the visit is to manage his diabetes and chronic pain. James has a known history of opioid use disorder.

Instead of avoiding the topic, the NP skillfully opens the conversation. Using open-ended, non-judgmental questions, she asks about his history of use and specifically inquires if he has been having cravings for opioids, especially given his ongoing struggle with chronic pain. This empathetic and direct approach creates a safe space for James to be honest.

James discloses that he has returned to using illicit fentanyl. He identifies the primary drivers of his use as his undertreated pain and depression. He had been on buprenorphine in the past but stopped, thinking he could manage on his own. “I thought I could do it without support,” he admits. Now, he recognizes he needs help and asks his NP about restarting buprenorphine.

The Shared Decision-Making Process

In response, the NP doesn’t just write a prescription. She engages James in shared decision-making. They discuss the different options for restarting buprenorphine, including the risks and benefits of each approach. They specifically talk about a high-dose initiation strategy (also known as the “Bernese Method” or microdosing), which allows a patient to start buprenorphine without having to go into full, severe withdrawal first. They mutually agree this is the best path for him.

The NP sends the buprenorphine prescription to a co-located pharmacy on the same campus as the clinic. This immediately removes the transportation barrier and the risk of the prescription getting lost or unfilled.

But the care doesn’t stop there. The NP and James address the drivers of his use: his pain and depression. They agree to submit referrals to a mental health counselor and a Chronic Pain Cognitive Behavioral Therapy (CBT) group, both of which are also offered on-site within the same clinic. To solidify this connection, the NP doesn’t just hand him a piece of paper. She performs a “warm handoff” by personally walking James down the hall and introducing him to the mental health counselor he will be seeing. This simple act dramatically increases the likelihood that James will follow through with the appointment and helps him feel that his care team is truly working together.

Follow-up and Stabilization

By the end of that single visit, James leaves the clinic with:

• A buprenorphine prescription in hand.
• A clear plan for how to initiate it.
• A scheduled check-in with the pharmacist for the next day.
• A scheduled telehealth follow-up appointment with his NP.
• Confirmed appointments with the counselor and the chronic pain group.

Over the next few days, James transitions onto buprenorphine. High-dose initiations require close monitoring, so short-interval telehealth follow-up is critical. During his call with the NP, James reports that getting to the point of moderate withdrawal needed to start the buprenorphine was challenging, but once he was on the medication, he felt much better. They work together to adjust his dose slightly to optimize its effectiveness.

During this call, the NP also introduced him by phone to a peer support specialist. This specialist, who has lived experience with recovery, can provide an extra layer of support, encouragement, and practical guidance as James navigates the early stages of his journey.

James ends the call feeling hopeful. He feels that he has a team he can trust and turn to if he struggles in the future. He is also immensely proud that he has not used fentanyl in two days—a monumental achievement.

Long-Term Integrated Care

In the future, James’s care is managed through this integrated, team-based model. He has regular visits with the nurse care manager, who coordinates his buprenorphine refills and urine toxicology testing, providing consistent support and monitoring. Simultaneously, he begins to address the root causes of his use by attending therapy for his depression and learning CBT skills to manage his chronic pain without opioids.

This case is, of course, an optimal scenario. I recognize that for many clinicians, especially those in under-resourced settings, this level of integrated service may feel aspirational. However, it is a model worth striving for because it highlights the profound importance of treating the whole person. As NPs and integrative practitioners, this is what we are trained to do.

It is also important to add a crucial caveat: for some patients, the level of support offered in a primary care setting is not sufficient to disrupt their substance use. It is therefore essential for all of us in primary care to know our local referral resources and be prepared to connect patients to a higher level of care, such as a specialty SUD treatment program, when needed.

Specialty SUD Treatment: When Primary Care Is Not Enough

When a patient’s treatment needs exceed what a primary care setting can provide, several specialty SUD treatment options exist. These programs offer a more intensive and structured environment to support recovery. Examples include:

• Intensive Outpatient Treatment (IOP): Patients attend therapy and group sessions for several hours a day, several days a week, while still living at home.
• Residential or Inpatient Rehab: Patients live at the treatment facility for a period of time (typically 30-90 days), receiving 24/7 support and intensive therapy.
• Office-Based Addiction Treatment (OBAT): Specialized outpatient clinics that focus primarily on providing medication for addiction treatment (MAT), often with integrated counseling.
• Opioid Treatment Programs (OTPs): The federally licensed clinics that are authorized to dispense methadone for the treatment of OUD.

A critical point to emphasize is that while behavioral interventions are a mainstay of these programs, participation in a behavioral program should not be a prerequisite for a patient to receive medical treatment for SUD. A patient with OUD can and should be able to start buprenorphine or naltrexone without being required to enroll in counseling simultaneously. While the combination is often ideal, medication alone is a life-saving intervention, and placing barriers in front of it can have tragic consequences.

Optimizing Your Wellness- Video

The Acute Care Setting: A Teachable Moment

Hospitals and emergency departments are often chaotic and stressful environments, but they also represent a critical opportunity to engage patients in SUD care. An overdose, a serious infection from injection drug use, or another medical crisis can serve as a powerful teachable moment—a point in time when an individual is re-evaluating their life and may be more open to considering treatment.

For patients who have avoided healthcare because of stigma, a positive, compassionate interaction during a hospitalization can be transformative. It can begin to repair their trust in the medical system and open the door to future engagement.

The gold standard for addiction care in the hospital setting is the inpatient addiction consult service. Research has shown that care from an addiction consult service significantly improves patient outcomes, including reducing hospital readmissions and increasing the number of patients who both start and continue on medications for opioid use disorder after discharge.

Deep Dive: The Inpatient Addiction Consult Service

An addiction consult service (ACS) is an interdisciplinary team of SUD experts who provide comprehensive care to hospitalized patients. The exact composition of the team can vary, but it typically includes:

• An Addiction Medicine Clinician: An MD, DO, NP, or PA with specialized training in addiction medicine who can assess the patient, manage withdrawal, and initiate medications like buprenorphine or methadone.
• A Social Worker: A specialist in psychosocial assessment who can use tools like the ASAM criteria, provide counseling, engage with the patient’s family (with consent), and begin the complex process of arranging for post-discharge treatment.
• A Care Coordinator: Personnel dedicated to the logistical challenges of connecting a patient to outpatient care, navigating insurance hurdles, and ensuring a smooth transition.
• A Peer Support Specialist: An individual with lived experience in addiction and recovery. This person’s role is invaluable. They can build rapport and trust in ways clinicians often cannot, provide emotional support, and help the patient navigate the confusing and often intimidating hospital system.

The function of an ACS extends beyond direct patient care. They also drive system-wide change within a hospital. This can include:

• Revising hospital policies to be more patient-centered and less stigmatizing.
• Leading quality improvement initiatives related to SUD care.
• Providing education to other healthcare professionals across the institution—doctors, nurses, pharmacists—on best practices for caring for patients with SUD.

A Clinical Case Study: Lisa’s Hospitalization with an ACS

Let’s examine how an ACS can support a patient during a complex hospital stay.

The Presentation

Lisa, a 32-year-old woman, presents to the emergency department with a seven-day history of a swollen, red, and warm left lower extremity. She is open with the care team, reporting daily use of both intravenous and inhaled fentanyl, as well as methamphetamines. Her last use was six hours ago, and she is starting to feel the intensely uncomfortable symptoms of opioid withdrawal.

As the team talks to her, she expresses significant anxiety about her dog, who she left with a friend. She’s not sure how long her friend can watch the dog, and this is a major source of stress. A review of her medical chart shows a positive test for active hepatitis C. When asked, she confirms she was told about it a while ago but hasn’t gotten around to treating it.

The ACS Intervention

Within 24 hours of Lisa’s admission, the ACS team is consulted and begins to engage her.

• The Medical Provider: The addiction medicine clinician meets with Lisa, performs a thorough assessment, and determines that she meets the criteria for severe opioid and methamphetamine use disorder. They discuss the options for managing her opioid withdrawal. After a conversation about the risks and benefits, Lisa and the provider decide to start methadone to stabilize her withdrawal symptoms, with a plan to transition her to buprenorphine once she is more stable. The provider also discusses harm reduction strategies and the limited but emerging treatment options for methamphetamine use disorder.
• The Social Worker: The ACS social worker meets with Lisa and completes a full ASAM assessment to understand her needs across all six dimensions. With Lisa’s permission, the social worker might reach out to her family for collateral information and to enlist their support. The social worker uses motivational interviewing to help Lisa feel supported and encourage her to stay in the hospital to complete her medical treatment. Hospital stays can be distressing for patients with SUD, and self-directed discharge is common. The ACS team’s support is crucial in preventing this. The social worker also discusses Lisa’s long-term goals and begins the referral process for residential treatment upon discharge.
• The Peer Specialist: The peer meets with Lisa and listens. They understand that her concern for her dog is not a trivial matter but a major barrier to her ability to focus on her health. The peer might provide Lisa with a cell phone and help her make arrangements for her pet’s care, relieving a huge source of anxiety.

Stabilization and Ongoing Care

Two days later, thanks to the ACS team’s coordinated efforts, Lisa’s situation has improved significantly.

• Her opioid withdrawal is stabilized on methadone, and the team begins the process of a low-dose initiation of buprenorphine, which will allow for a smooth transition without precipitating withdrawal.
• She has been diagnosed with cellulitis in her leg and has started IV antibiotics.
• Her active hepatitis C has been confirmed, and a referral has been placed for outpatient treatment.
• She continues to voice cravings for methamphetamines, a challenge the team will continue to address.

As her hospital stay continues, the ACS team provides comprehensive support:

• For her cellulitis: They coordinate with the primary medical team and help arrange a follow-up appointment with a PCP who is experienced in caring for patients with SUD.
• For her stimulant use disorder: They discuss evidence-based behavioral treatments like contingency management (which provides incentives for abstinence) and may discuss off-label medications that can sometimes help reduce cravings.
• For harm reduction: They provide crucial education on the risk of fentanyl contamination in the drug supply, the importance of carrying naloxone (the opioid overdose reversal drug), and the risks of transmitting infectious diseases like HIV and hepatitis C through sharing substance use paraphernalia.

Integrative Care Transitions for SUD: Why Continuity and Collaboration Matter

When I reflect on patients navigating the difficult pivot from hospital to home, I see a consistent truth: continuity saves lives. If I start a patient on buprenorphine in the hospital, and then I personally (or a known team member) see them soon after discharge in a bridge clinic, that relational continuity dramatically improves retention. This is not simply a convenience—it is a neurobiological and behavioral lever that builds trust, retains the therapeutic alliance, and lowers the friction of recovery.

Here is how we operationalize continuity and why it works:

• Continuity of providers across acute and community settings: We ensure the hospital clinician or a unified care team member also conducts early post-discharge follow-up (e.g., bridge clinic) within 3–7 days. This works because early recovery is a window of neuroplastic vulnerability and hope. Keeping the same provider reduces uncertainty and decision fatigue, stabilizes the reward-learning loop with consistent reinforcement, and reduces “care handoff gaps” where patients often disengage.
• Bridge prescriptions at discharge for SUD medications: When initiating MOUD (e.g., buprenorphine) in the hospital, we send patients home with at least 10–14 days of medication. This is important because this buffer prevents an abstinence-only interlude and reduces relapse risk by maintaining mu-opioid receptor occupancy. It buys time for clinic appointments, transportation logistics, and insurance processing.
• Co-located services and flexible care modalities: Wherever possible, we offer co-located services (medical care, SUD treatment, mental health, social support) and telehealth options for follow-ups when that suits patient responsibilities. Co-location reduces friction and enhances care coherence. Telehealth engages those with childcare, transportation barriers, health anxiety, or precarious work schedules.
• Care navigators as bridge architects: Our care navigators map local resources, guide insurance steps, and coordinate referrals and follow-ups. Navigation transforms a maze into a map, minimizing administrative burden on patients already taxed by withdrawal, cravings, or postpartum demands.

These elements are the backbone of an integrative model that centers the human realities of recovery. At our clinic in El Paso, we layer this with functional medicine evaluations, chiropractic and biomechanical care for pain and movement, and internal medicine oversight to ensure safety, equity, and alignment with each person’s goals.

The Critical Challenge of Care Transitions

A care transition occurs whenever a patient moves from one treatment setting to another. This could be a discharge from the hospital to an outpatient clinic, or a move from a less intensive program (like a weekly therapy appointment) to a more intensive one (like residential treatment).

These transitions are points of extreme vulnerability for patients. They are fraught with challenges that can easily derail a patient’s recovery:

• Care Silos: Different clinics and hospitals often operate in their own bubbles, with poor communication and little partnership. Medical records don’t get transferred, and the receiving facility has little information about the patient’s history or recent treatment.
• Stigma: Patients can experience stigma not only from healthcare providers but also from staff at treatment facilities, which can make them reluctant to engage.
• Staff and Provider Shortages: Just as there is a shortage of PCPs, there is a severe shortage of addiction counselors, social workers, and beds in treatment facilities, leading to long waitlists and gaps in care.
• Lack of Patient Resources: Many patients lack the basic resources needed to navigate these transitions, such as transportation to get to appointments, a phone or internet access for telehealth visits, or stable housing.
• Insurance Barriers: Navigating insurance requirements, prior authorizations, and coverage limitations is a nightmare for patients and providers alike, often creating delays that can be devastating.

A scoping review that examined best practices for transitions from acute care to community settings identified a key strategy: wherever possible, we must leverage existing community partnerships and establish clear lines of communication between treatment agencies. Breaking down the silos is essential for creating a safety net for our patients.

Why Continuity Improves SUD Outcomes: The Neurobiology and Behavior

The science supports what we observe clinically. The therapeutic alliance activates reward, safety, and trust pathways. Oxytocinergic and prefrontal circuits involved in social bonding can mitigate stress reactivity in the amygdala and support adherence. Behavioral economics research shows decreased “present bias” when trusted relationships increase future-oriented valuation.

MOUD, such as buprenorphine, maintains receptor occupancy and dampens craving. Buprenorphine’s high affinity for mu-opioid receptors and its partial agonist activity stabilizes dopaminergic reward signaling while reducing withdrawal. Methadone’s full agonism provides steady-state coverage. Bridge prescriptions prevent the receptor “vacuum” that can precipitate reuse after a period of abstinence.

Co-located and telehealth services reduce the “cost” of seeking care. Every systemic friction—transportation, scheduling, paperwork—is a behavioral toll. As noted in a study on physician time, reducing administrative burdens is key. Fewer tolls mean more follow-through. Care navigators further improve care transitions by decomplexifying system barriers. Navigation consistently enhances linkage and retention in chronic disease care, and these effects are increasingly evident in SUD care. Together, these dynamics translate into better initiation, stabilization, and continuation of care.

Justice-Involved Individuals: Unique Risks and Essential Interventions

Justice-involved individuals face a perilous period immediately after release from incarceration. Overdose is a leading cause of death post-release, a tragic outcome driven by a specific physiological change: the loss of tolerance.

• Physiological Context: During a period of abstinence in a controlled environment like a jail or prison, the body’s neuroadaptation to chronic opioid exposure reverses. Opioid receptors, which were downregulated (decreased in number) and desensitized to cope with high levels of stimulation, revert toward their baseline state. When a person is released and returns to using the same dose they used before incarceration, that dose can now be fatal because their physiologic capacity to handle it has been drastically reduced. This is compounded by the high-stress environment of reentry, which dysregulates the HPA axis and challenges impulse control and decision-making.
• Systemic Barriers: This physiological risk is amplified by systemic failures, including loss of insurance, limited MOUD access inside facilities (or subtherapeutic dosing when available), and the immense stigma and administrative complexity of re-engaging with care.

Best practices we implement to mitigate these risks include:

• Initiating or continuing MOUD pre-release with a confirmed post-release clinic appointment scheduled within 72 hours.
• Providing naloxone and comprehensive overdose education upon release.
• Assigning a care navigator to assist with benefits reactivation (e.g., Medicaid), retrieving identification, scheduling appointments, and planning transportation.
• Coordinating with probation or parole officers to align care requirements and appointments.
• Aggressively addressing pain without reliance on short-acting opioids, using chiropractic care, graded exercise, soft-tissue therapy, and non-opioid pharmacology under Dr. Cardenas’s oversight.

Integrating chiropractic and rehabilitation post-release is crucial. It helps restore the functional capacity needed for employment, reduces pain-related relapse triggers, and supports self-efficacy—all of which are critical for avoiding recidivism and building a life in recovery.

Peripartum Care: Reducing Harm, Respecting Autonomy, and Supporting Engagement

Pregnant and parenting patients with SUD face a crushing combination of systemic stigma and profound legal fears that frequently drive them away from care. This avoidance tragically increases the risk for both overdose and adverse maternal-fetal outcomes.

Key realities to understand:

• Substance use alone is not the definition of maltreatment. Federal statutes, specifically the Comprehensive Addiction and Recovery Act (CARA), require healthcare providers to notify child protective services when an infant is born “affected by” substances. However, this notification does not automatically equate to a report of suspected abuse or neglect. States vary widely in how they interpret this and what thresholds trigger an investigation.
• Punitive state policies correlate with worse prenatal engagement. Cross-sectional evidence indicates that states with stricter punitive or mandatory reporting regimes are associated with later initiation and reduced adequacy of both prenatal and postpartum care among women who use substances during pregnancy.
• Fear of custody loss and criminalization drives disengagement. The rational fear of having one’s child taken away or facing criminal charges causes many pregnant individuals to avoid the healthcare system altogether. The result is more preventable overdoses, less prenatal care, and worse outcomes for both parent and child.

Our clinical implications are clear:

• Provide non-judgmental, person-centered care. We start visits with warmth and an acknowledgment of the barriers: “Thank you for coming to see me today. I know it can be hard.” We honor the patient’s goals while providing clear, evidence-based counsel on risks and treatments.
• Offer MOUD in pregnancy with honest counseling. Both buprenorphine and methadone are safe and recommended in pregnancy. The risks of unmanaged withdrawal to the parent and fetus—including fetal distress and demise—typically far outweigh the risks of the medication. We must also discuss neonatal opioid withdrawal syndrome (NOWS). It is a real and manageable condition; it is not strictly dose-dependent, and research shows that outcomes improve significantly with supportive care practices like rooming-in and breastfeeding.
• Manage dose dynamics across trimesters and postpartum. Higher doses of MOUD may be needed in the third trimester due to increased volume of distribution, hepatic enzyme induction, and placental factors. Postpartum, as metabolism gradually normalizes over approximately 3–12 weeks, dose reductions should be individualized, carefully monitoring for both sedation (if the dose is too high) and cravings (if it’s too low).
• Create smooth transitions postpartum. We use flexible visit times, telehealth options, and help with transportation and childcare to reduce attrition. Warm handoffs to mental health providers increase follow-through. We also engage social supports like peer counselors, social workers, and housing and food resources. Even small scaffolds can stabilize the fragile early postpartum weeks.

Case Reflection: Postpartum Transitions for a Patient on Buprenorphine

Consider a patient like Liz, age 32, who is one day postpartum after delivering a healthy baby girl. She has OUD with a history of illicit fentanyl use and started buprenorphine during her pregnancy. By the third trimester, her dose was stabilized at 8 mg four times daily (32 mg/day) to manage cravings.

My approach would be:

• Focus on the mother-baby dyad first. If the newborn is being monitored for NOWS, I ensure Liz has the support she needs to visit and participate in care. This could mean arranging transportation vouchers, flexible scheduling, and strongly advocating for rooming-in when possible, as maternal presence is known to improve neonatal regulation and reduce the need for pharmacologic treatment of NOWS.
• Manage her buprenorphine dose. I would explain to Liz that as her postpartum metabolism returns to baseline, her buprenorphine needs may decrease. We would monitor closely for signs of sedation, adjust her dose cautiously in the 3–12-week window, and never rush tapering at the expense of craving control.
• Provide flexible follow-up. Early and frequent touchpoints via telehealth or in-person visits are crucial, depending on her needs and resources. Our navigator would assist with applications for WIC, housing support, formula/feeding supplies, and pediatric follow-ups.
• Address her pain and function. I would provide gentle postpartum chiropractic care to address common issues like pelvic girdle pain, low back strain, and thoracic stiffness from feeding postures. We would also develop a home exercise program for pelvic floor and transverse abdominis engagement to support core stability and reduce pain-related stress.
• Integrate social and mental health supports. We facilitate warm handoffs to counseling and encourage connections with peer support groups. We screen for postpartum depression and anxiety, and Dr. Cardenas coordinates any necessary psychopharmacology with her MOUD to ensure safety.

The rationale is simple: stabilized dosing, reliable supportive touchpoints, and functional recovery build safety and confidence. In recovery, small, consistent gains compound over time.

Adolescents: Developmental Considerations, Consent, and Practical Supports

Treating adolescents with SUD requires a tailored set of strategies that account for their unique neurodevelopmental stage and social context.

• Neurodevelopment matters. The adolescent brain has a highly active reward system, while the prefrontal cortex, which governs executive functions like impulse control and long-term planning, continues maturing into the mid-20s. This means adolescents experience potent reward signals from substances with less mature “braking” capacity. Their motivations for use also differ from adults and may include peer belonging, self-medication for anxiety or depression, body image concerns, or experimentation.
• High comorbidity and polysubstance use are common. We frequently see SUD co-occurring with depression, anxiety, ADHD, and trauma histories. Each of these can shape substance use patterns and must be addressed concurrently.
• Dependency patterns can be variable. Some adolescents use episodically rather than daily, which influences the risk-benefit profile for MOUD. An 8 mg starting dose of buprenorphine, for example, might be appropriate for a dependent adult but could oversedate an opioid-naive or episodic adolescent user.
• Retention in care is challenging. Barriers include scheduling conflicts with school and sports, fear of disclosure to parents or school officials, and parental consent requirements, which vary by state. It is essential to know your state’s laws for minor consent to SUD care. When possible, we obtain adolescent assent and encourage supportive parental involvement.

Medications for Opioid Use Disorder in Youth

• Buprenorphine: This is the first-line MOUD for adolescents and young adults. It is FDA-approved for age 16 and older. Some specialists use it off-label in patients as young as 12 in select cases, which requires a very careful consent process and risk-benefit discussion with both the adolescent and their guardians. Evidence for use under 18 is limited, and there are no robust trials on long-acting injectable buprenorphine in minors; LAIs are not approved for use under 18.
• Naltrexone and Methadone: These are generally approved for ages 18 and older. Their use in younger adolescents is rare and highly specialized.

Our clinical practice for adolescents involves:

• Wraparound care: We integrate mental health therapy, family-based interventions where appropriate, school coordination, and harm reduction education. We provide naloxone widely and teach overdose recognition.
• Individualized MOUD decisions: For an episodic user without physical dependence, we discuss all risks and benefits, and may consider non-MOUD strategies paired with intensive therapy and harm reduction, or a microdosing initiation if MOUD is chosen.
• Engagement strategies: We offer flexible visit times, use telehealth when appropriate, and maintain a non-judgmental tone that respects their growing autonomy. We provide clear education about the dangers of counterfeit pills and fentanyl contamination; data show that targeted education reduces willingness to misuse.

Reporting Considerations in Pregnancy: Clarity, Compassion, and Compliance

A common misconception among providers is that any substance use in a pregnant person requires a mandatory report to child protective services (CPS) for abuse or neglect. This is not uniformly accurate.

• Federal law (CARA) requires notification, not necessarily a CPS report. The law mandates that a Plan of Safe Care be developed and that appropriate health and social service agencies be notified when an infant is born affected by substances. It does not mandate that every such case be reported as suspected abuse or neglect.
• States determine the response. States have the authority to define what constitutes child abuse and neglect and to determine whether a CARA notification triggers an investigation.
• Punitive approaches deter care. As previously mentioned, evidence links punitive reporting environments with delays in prenatal care and reduced postpartum engagement.
• Patient-centered messaging is key. We must be transparent with patients. We explain the legal requirements in our state and how our team will support the family through the process. The emphasis should always be on treatment and support, not punishment.

At our clinic, Dr. Cardenas leads our compliance with all state and federal requirements. We prioritize developing a comprehensive Plan of Safe Care that centers on treatment and social support, coordinated with OB and pediatric providers. We actively avoid stigmatizing language and approaches, focusing instead on safety, stability, and engagement.

Medications for Opioid Use Disorder in Pregnancy: Pharmacology, Physiology, and Counseling

MOUD saves lives in pregnancy and postpartum. Here’s how we explain it and manage it:

• Buprenorphine and methadone are safe and recommended in pregnancy. The rationale is that unmanaged withdrawal increases maternal stress, circulating catecholamines, and uterine irritability, which poses risks for fetal distress and miscarriage. MOUD stabilizes maternal physiology and dramatically reduces the risk of overdose, the leading cause of maternal mortality in this population.
• Neonatal Opioid Withdrawal Syndrome (NOWS) must be demystified. It is not strictly dose-dependent; maternal steady-state stability is more important than striving for the “lowest possible” dose if that dose under-treats cravings. Outcomes for NOWS are significantly improved with nonpharmacologic care like rooming-in, breastfeeding when appropriate, and standardized supportive care protocols.
• Dosing dynamics change during pregnancy. In the third trimester, increased blood volume, augmented CYP enzyme activity, and enhanced renal clearance can necessitate higher or more frequent (split) doses of MOUD to maintain stability. Postpartum, as metabolism normalizes over 3–12 weeks, we taper the dose only if cravings are controlled, sedation emerges, or the patient desires a gradual reduction. We monitor closely for sedation, especially if other sedating agents are being used.
• Practical bridge strategies are essential. We provide bridge prescriptions at discharge, ensure early follow-up in a familiar clinic, and provide clear education about dose expectations and symptom monitoring.

The Role of Integrative Chiropractic in SUD Recovery

Now, I want to discuss an area of care that is often overlooked in SUD treatment but holds immense potential: integrative chiropractic care. As a Doctor of Chiropractic, I have seen firsthand how structural and neurological health are deeply intertwined with addiction and recovery.

Many individuals with SUD also suffer from chronic pain. In fact, chronic pain is often the initial reason a person is prescribed opioids, leading to dependence and, for some, a transition to illicit substances. The physical discomfort, inflammation, and neurological sensitization associated with chronic pain create a state of constant physiological stress. This stress drives the brain’s reward-seeking behavior, making substance use a form of self-medication to numb both physical and emotional pain temporarily.

This is where chiropractic care, integrated within our multidisciplinary framework, can be transformative.

Restoring Spinal Health and Neurological Function

• Spinal Adjustments (Spinal Manipulative Therapy): The spine is the central conduit for the nervous system. Misalignments, or subluxations, can interfere with nerve signaling and contribute to pain and muscle tension. Through precise, gentle adjustments, we restore proper motion to spinal joints. This does more than relieve back or neck pain; it can profoundly affect the central nervous system. Research suggests that spinal manipulation can modulate pain perception by influencing the periaqueductal gray (PAG) and other pain-processing centers in the brain. It can also help downregulate the sympathetic nervous system (“fight-or-flight”) and upregulate the parasympathetic nervous system (“rest-and-digest”). For a person in recovery, who is often living in a state of hyper-arousal and anxiety, this shift towards a more balanced autonomic state is incredibly therapeutic.
• Soft Tissue and Myofascial Release: Chronic stress and pain lead to tight, painful knots in muscles and fascia called trigger points. We use techniques like massage therapy, trigger point therapy, and myofascial release to break up these adhesions, improve circulation, and reduce muscle tension. This provides immediate physical relief and can help reduce a patient’s reliance on pain as a driver for substance use.

Addressing the HPA Axis and Stress Response

Addiction and the stress of early recovery place an enormous burden on the Hypothalamic-Pituitary-Adrenal (HPA) axis, the body’s central stress response system. Chronic activation leads to elevated levels of the stress hormone cortisol, which can cause inflammation, sleep disruption, anxiety, and cravings. Chiropractic adjustments have been shown to help normalize HPA axis function. By reducing physical stressors and modulating nervous system activity, chiropractic care can help lower cortisol levels and restore a healthier stress response. This is a crucial physiological step in supporting long-term recovery.

How Integrative Chiropractic Care Fits Across SUD Scenarios

In every scenario—post-hospital discharge, justice reentry, pregnancy/postpartum, and adolescence—pain and movement limitations can undermine recovery. Our chiropractic and rehabilitation strategies address these barriers:

• Reduce pain drivers: We treat joint restrictions, myofascial trigger points, postural strain, and movement dysfunctions with evidence-informed manual therapy and progressive exercise.
• Improve sleep and mood: Pain reduction improves sleep quality; better sleep reduces stress hormones and cravings.
• Build self-efficacy: Functional gains (lifting, walking, caring for infants) translate directly to confidence and adherence.
• Coordinate safely with MOUD and medical care: Cardenas and I communicate about sedation risks, hemodynamics, and contraindications. Our care plans are synchronized.
• Tailor for special populations: For prenatal/postpartum patients, we use modified techniques and focus on pelvic stabilization. For justice-involved individuals, we focus on return-to-work conditioning. For adolescents, we align rehab with their sport or activity identity.

Functional Medicine Foundations for SUD Recovery

Functional medicine complements MOUD and counseling by stabilizing the biological systems that modulate mood, stress, and pain. Under Dr. Cardenas’s oversight, I assess and target:

• Nutritional Deficiencies and Metabolic Health: Chronic substance use depletes the body of essential vitamins and minerals (e.g., magnesium, B-vitamins) needed for neurotransmitter production. We also address insulin resistance and anemia, which can worsen fatigue and mood.
• Inflammation and Gut Health: The gut-brain axis is a critical communication pathway. Substance use disrupts the gut microbiome, leading to inflammation that affects mood, cravings, and brain function. Optimizing diet, sleep, and activity levels helps.
• Sleep Architecture: Sleep deprivation amplifies craving via dopaminergic and cortisol pathways. We use behavioral sleep strategies and non-sedating supports.
• Movement and Nervous System Regulation: Graduated exercise, breathwork, and vagal tone exercises support stress resilience and pain modulation.

The rationale is straightforward: a stabilized biological terrain makes the psychological work of recovery more achievable.

Emerging Frontiers: Genetics and GLP-1 Agonists

Genetics and Addiction Risk: Promise and Limitations

Genetic research is advancing our understanding of SUD risk as a polygenic phenomenon. While some companies now market genetic tests claiming to identify risk, their clinical utility remains limited. Genetics contributes moderately to risk, but it always interacts with environmental factors. Today, large, well-controlled trials showing that such testing improves outcomes are lacking. Ethical concerns about stigma, privacy, and bias also persist. Our stance is to focus on modifiable risks and proven interventions, while remaining attentive to evolving evidence.

GLP-1 Receptor Agonists: A New Frontier in SUD Treatment?

Early research suggests GLP-1 receptor agonists (e.g., semaglutide, liraglutide) may reduce alcohol intake and correlate with lower medical encounters for other SUDs. A recent randomized controlled trial found reduced alcohol consumption in adults with alcohol use disorder, and real-world data analyses have shown similar associations. The proposed mechanisms involve modulation of the brain’s reward pathways.

However, the evidence is still evolving. These medications have significant side effects and costs. Our approach is to monitor the evidence, consider consultation for carefully selected patients (particularly those with co-existing metabolic disease), but not to position GLP-1s as a first-line SUD treatment. MOUD, counseling, and harm reduction remain foundational.

Clinical Observations from Our Practice

Drawing from my work at Injury Medical Clinic PA and my professional platforms, a few patterns stand out:

• Patients with stabilized pain and improved movement adhere better to MOUD and have fewer missed appointments.
• Early postpartum support—especially flexible scheduling and telehealth—prevents many from dropping out of care.
• Justice-involved patients benefit when exercise and manual therapy are framed as tools for work readiness and stress regulation.
• Adolescents engage more when we align rehab with their sport or activity identity and provide clear, non-judgmental harm reduction education.

These observations align with biopsychosocial models of pain and recovery, confirming that addressing the body, brain, and behavior together yields more durable outcomes.

Conclusion: Building a Future of Hope and Healing

The landscape of Substance Use Disorder treatment is at a critical juncture. We are armed with a deeper understanding of the neurobiology of addiction, more effective medications, and innovative models of care. Yet, we are still faced with enormous systemic barriers, from provider shortages to the persistent, damaging effects of stigma.

The path forward lies in collaboration, integration, and compassion. It requires us to break down the silos between primary care, specialty treatment, and acute care. It demands that we embrace team-based approaches, empowering every member of the team—from the medical director to the nurse practitioner, the chiropractor, the social worker, and the peer specialist—to work at the top of their license. It means integrating physical treatments like chiropractic care with medical and psychological interventions to address the whole person.

Most importantly, it requires a fundamental shift in our mindset. We must move away from a model that views patients with suspicion and judgment and towards one that recognizes their inherent strength and capacity for change. By creating safe, supportive, and non-stigmatizing environments, we can build the trust that is necessary for healing to begin. As we continue to advance our clinical knowledge and refine our treatment models, let us never lose sight of the person at the center of it all—an individual deserving of dignity, respect, and the very best care we have to offer.

References

• American College of Obstetricians and Gynecologists (ACOG). (2017). Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy.
• American Society of Addiction Medicine. (n.d.). The ASAM criteria.
• Binswanger, I. A., et al. (2013). Release from prison — A high risk of death for former inmates. New England Journal of Medicine, 356(2), 157–165.
• Chan, B., et al. (2020). A scoping review of care transitions from acute to community-based settings for patients with substance use disorders. Journal of Substance Abuse Treatment, 112, 1-10.
• Eccleston, C., et al. (2020). Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database of Systematic Reviews.
• Faherty, L. J., et al. (2022). Association of punitive prenatal substance use policies with infant and maternal outcomes. JAMA Network Open, 5(5): e2210098.
• Klausen, M. K., et al. (2022). Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. eBioMedicine, 81, 104123.
• Kresina, T. F., & Lubran, R. (2011). Improving public health through access to medication-assisted treatment. Journal of Addictive Diseases, 30(3), 273–283.
• La-Belle, M., et al. (2018). Models of care for integrating opioid use disorder treatment in primary care settings: A systematic review. Journal of General Internal Medicine, 33(12), 2165–2176.
• MacMillan, K., et al. (2018). Association of rooming-in with outcomes for neonatal abstinence syndrome: A systematic review and meta-analysis. JAMA Pediatrics, 172(4), 345–351.
• Nielsen, S., et al. (2019). Opioid-sparing effects of analgesic strategies: A systematic review. Anesthesia, 74(S1), 110–120.
• Sinsky, C., et al. (2016). Allocation of physician time in ambulatory practice: A time and motion study. Annals of Internal Medicine, 165(11), 753–760.
• Substance Abuse and Mental Health Services Administration. (n.d.). Provider Clinical Support System (PCSS).
• Substance Abuse and Mental Health Services Administration. (n.d.). gov.
• Substance Abuse and Mental Health Services Administration (SAMHSA). (2018). Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants.
• Valaitis, R., et al. (2017). Navigating the complexity of community health: A scoping review on patient navigation. International Journal for Equity in Health, 16, 40.
• Wang, L., et al. (2024). GLP-1 receptor agonists and risk of substance use disorders: A claims-based cohort analysis. (Nature Communications)

SEO Tags: Substance Use Disorder, SUD Treatment, Integrative Medicine, Chiropractic Care, Nurse Practitioner, Buprenorphine, Methadone, Functional Medicine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso TX, Addiction Consult Service, ASAM Criteria, Care Transitions, Chronic Pain, HPA Axis, Multidisciplinary Care, Primary Care, Opioid Use Disorder, Harm Reduction, Recovery, integrative chiropractic care, MOUD in pregnancy, postpartum buprenorphine, justice-involved reentry overdose risk, adolescent opioid use disorder, care transitions SUD, bridge clinic prescriptions, co-located services SUD, telehealth addiction care, neonatal opioid withdrawal syndrome, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, functional medicine addiction, chiropractic pain management in recovery